Amarantus BioScience Holdings, Inc. – “Amarantus Shareholder Update: Fundamental Progress on the Pipeline and Strategy Continues”

NEW YORK, NY / ACCESSWIRE / March 26, 2015 / Amarantus BioScience Holdings, Inc. (OTCQB:AMBS) today published a new blog post on The Chairman’s Blog, written by the Company’s President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Commissiong provides an update on progress Amarantus has made in the Diagnostic and Therapeutics divisions, as well as highlights the Company’s business strategy and key milestones expected to be achieved in 2015. Read the full blog post from Mr. Commissiong on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/amarantus-shareholder-update-fundamental-progress-pipeline-strategy-continues/).

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS has licensed Eltoprazine, a Phase 2b ready small molecule indicated for Parkinson’s disease Levodopa-induced dyskinesia and adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test, (LymPro Test(R)), which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (“MANF”) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard(TM)).

In November 2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns.

On January 12, 2015, AMBS announced the acquisition of DioGenix, Inc., a specialized neuro-diagnostics company, and owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. On January 15, 2015, AMBS executed a one-year exclusive option agreement with Georgetown University to enter into a license for the patent rights related to certain blood based biomarkers for memory loss and Alzheimer’s disease jointly owned by Georgetown University and University of Rochester. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.

SOURCE: TheChairmansBlog.com

ReleaseID: 427242